“Number one in Asia is what we are shooting for”
By Kim, Jin-Gu | translator Byun Kyung A
19.11.21 06:20:35
가나다라
0
“Generic industry facing crisis and opportunity all at once, only way out is the global market”
“Beyond Korean market, aiming for Asia’s top dermatological treatment company”
“For next 50 years, Dongkoo’s future engine is in bio sector”
![](http://pds.dreamdrug.com/newseng_images/201911/137_1.jpg)
“As far as dermatological treatment business goes, I think we have a shot at becoming the number one in Asian market”, Cho Yong-joon, CEO at Dongkoo Bio & Pharma (“Dongkoo”) commented. The CEO said ‘entering global market’ is the next long-term goal for the company while it gets closer to its 50th anniversary next year.
CEO Cho was confident that Dongkoo’s two most prominent business sectors, dermatological treatment and contract manufacturing, would both be competitive in the global market. He explained the recent aggressive investment and company expansion have been executed with the global market in mind.
Visiting his office on Nov. 18 for an interview, it has not even been
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)